Dzianis Babrou - Oasmia Pharmaceutical Head Devel
OASMYDelisted Stock | USD 0.06 0.00 0.00% |
Insider
Dzianis Babrou is Head Devel of Oasmia Pharmaceutical AB
Phone | 46 18 50 54 40 |
Web | https://www.vivesto.com |
Oasmia Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of (0.0875) % which means that it has lost $0.0875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2542) %, meaning that it generated substantial loss on money invested by shareholders. Oasmia Pharmaceutical's management efficiency ratios could be used to measure how well Oasmia Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Michael Hummel | STMicroelectronics NV ADR | 60 | |
Denise Grode | Cirrus Logic | 49 | |
J Reese | Small Cap Premium | 60 | |
Celine Berthier | STMicroelectronics NV ADR | N/A | |
Thomas Buttacavoli | Small Cap Premium | 42 | |
Todd Schively | Cedar Realty Trust | N/A | |
Todd Sinai | Small Cap Premium | 50 | |
Frank Filipps | Small Cap Premium | 72 | |
Dominique Mielle | Small Cap Premium | 51 | |
Nicholas Partenza | Cedar Realty Trust | N/A | |
Gilbert Nathan | Small Cap Premium | 40 | |
Julius Erving | Small Cap Premium | N/A | |
Lisha Parmar | Iris Acquisition Corp | 39 | |
Tyler Henshaw | Kite Realty Group | N/A | |
Thomas Major | Pyrophyte Acquisition Corp | 37 | |
Derrick Burks | Kite Realty Group | 64 | |
Dean Papadakis | Kite Realty Group | N/A | |
Andrea Petro | Small Cap Premium | 68 | |
Crystal Plum | Cedar Realty Trust | 41 | |
Remi Ouazzane | STMicroelectronics NV ADR | N/A | |
Jack Ross | Small Cap Premium | 62 |
Management Performance
Return On Equity | -0.25 | ||||
Return On Asset | -0.0875 |
Oasmia Pharmaceutical Leadership Team
Elected by the shareholders, the Oasmia Pharmaceutical's board of directors comprises two types of representatives: Oasmia Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oasmia. The board's role is to monitor Oasmia Pharmaceutical's management team and ensure that shareholders' interests are well served. Oasmia Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oasmia Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kai Wilkinson, Chief Officer | ||
Urban Ekelund, IR Mang | ||
Henrik Rnnberg, Chief Health | ||
John Cosby, Head Affairs | ||
Robert Maiorana, Head CFO | ||
Dzianis Babrou, Head Devel | ||
Christer MD, Acting Officer | ||
Reinhard Koenig, Chief Officer | ||
Johanna Rostin, Head Affairs | ||
Maria Hagberg, Head Affairs |
Oasmia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oasmia Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.25 | ||||
Return On Asset | -0.0875 | ||||
Current Valuation | 6.58 M | ||||
Shares Outstanding | 179.35 M | ||||
Number Of Shares Shorted | 20.72 K | ||||
Price To Book | 0.68 X | ||||
Price To Sales | 31.16 X | ||||
Revenue | 26.19 M | ||||
Gross Profit | (15.25 M) | ||||
EBITDA | (97.54 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Oasmia Pink Sheet
If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |